Unique ID issued by UMIN | UMIN000025110 |
---|---|
Receipt number | R000028872 |
Scientific Title | Development of the hepato-biliary-pancreatic tumor-specific imaging technique on targeting amino acid transporter |
Date of disclosure of the study information | 2017/01/01 |
Last modified on | 2018/02/01 11:37:14 |
Development of the hepato-biliary-pancreatic tumor-specific imaging technique on targeting amino acid transporter
Development of the novel tumor-specific imaging technique
Development of the hepato-biliary-pancreatic tumor-specific imaging technique on targeting amino acid transporter
Development of the novel tumor-specific imaging technique
Japan |
hepatocellular carcinoma,biliary tract cancer,pancreatic cancer
Hepato-biliary-pancreatic medicine |
Malignancy
NO
To develop the novel imaging technique for hepato-biliary-pancreatic tumor
Safety,Efficacy
Intratumoral accumulation and distribution of the PET probe ([18F]AA-7 and [18F]FDG) before and after treatment
Interventional
Parallel
Non-randomized
Open -no one is blinded
No treatment
2
Diagnosis
Medicine |
[18F]AA-7
[18F]FDG
20 | years-old | <= |
80 | years-old | > |
Male and Female
Patients
1) with hepato-biliary-pancreatic tumor in Osaka City University Hospital, who give informed consent.
Diagnostic criteria
Hepatocellular carcinoma: imaging (ultrasonography, CT, MRI, angiography), tumor marker (AFP, PIVKA-2), pathological diagnosis
Biliary and pancreatic tumor: imaging (ultrasonography, CT, MRI, angiography, ERCP) , tumor marker (CEA, CA19-9, SPAN-1, DUPAN-2), pathological diagnosis
2) who is between 20 and 80 years old (regardless of sex)
3) who give informed consent
4) who can be hospitalized before examination for controlling blood sugar and amino acid levels
5) who can survive more than six months
6) who can reach the ECOG score 0 or 1
Patients
1) with serious brain and/or kidney disease
2) with a history of chemotherapy
3) with pregnancy women
4) with claustrophobia
5) with grade C of Child-Pugh score (Hepatocellular carcinoma)
6) who are judged as not suitable for participation in this study
60
1st name | |
Middle name | |
Last name | Norifumi Kawada |
Osaka City University Graduate School of Medicine
Department of Hepatology
1-4-3 Asahimachi, Abeno-ku, Osaka 545-8585, Japan
06-6645-3905
kawadanori@med.osaka-cu.ac.jp
1st name | |
Middle name | |
Last name | Satoshi Nozaki |
Osaka City University Graduate School of Medicine
Department of Physiology
1-4-3 Asahimachi, Abeno-ku, Osaka 545-8585, Japan
06-6645-3711
satoshi.nozaki@riken.jp
Osaka City University
MEXT
Japanese Governmental office
NO
大阪市立大学医学部付属病院(大阪府)
2017 | Year | 01 | Month | 01 | Day |
Unpublished
Completed
2017 | Year | 01 | Month | 01 | Day |
2017 | Year | 01 | Month | 01 | Day |
2016 | Year | 12 | Month | 01 | Day |
2018 | Year | 02 | Month | 01 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000028872
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |